CHICAGO ( TheStreet) --No rest for the weary, even on Sunday, at the American Society of Clinical Oncology (ASCO) annual meeting underway in Chicago.

This is the second full day of clinical data presentations at ASCO 2010, highlighted by the plenary session this afternoon that will feature highly anticipated results from a phase III study of Bristol-Myers Squibb's ( BMY) melanoma drug ipilimumab.

Celgene ( CELG - Get Report), Amgen ( AMGN), Nektar Therapeutics ( NKTR - Get Report), Oxigene ( OXGN), ImmunoCellular Therapeutics ( IMUC.OB) and Cell Therapeutics ( CTIC - Get Report) are among the many companies also presenting clinical data today. Later tonight, Roche, Arqule ( ARQL) and Celgene are holding investor events in hotels near the ASCO meeting.

Follow this live blog throughout the day for continuous updates and reports from the ASCO meeting. I'll be reporting on clinical data presentations as I see and hear them, and I'll be blogging from the hallways, exhibition hall and meeting rooms, giving you a real-time perspective on all the investor-worthy buzz. With my iPhone and some nifty software, I'll even try to bring you photos and audio for an even deeper perspective.

I welcome your comments and questions on this live blog, too, which I'll do my best to answer and publish as time permits. You can also follow my ASCO 2010 coverage on Twitter.

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.